How regulators decide whether nutrition evidence is “good enough”

That’s because regulators don’t assess evidence based on volume or novelty. They assess it based on quality, consistency, relevance, and decision logic – all within a conservative regulatory framework designed to minimise consumer risk.

Understanding how this assessment actually works is critical for avoiding claims that sound defensible in theory but fail in practice.

Evidence is assessed as a body, not as individual studies

A common misconception is that a single strong study can justify a claim. In reality, regulators assess the totality of evidence, not isolated findings. Individual studies are not evaluated in isolation – evidence is synthesised to determine whether conclusions are reliable and reproducible, and gaps, inconsistencies, or limitations are weighed alongside positive findings.

A well-designed trial may strengthen a case, but it does not override weaknesses in the broader evidence base.

Grading frameworks: how study quality is judged

Regulators apply structured grading frameworks to assess the strength and reliability of evidence. While specific tools differ by jurisdiction and claim pathway, they generally evaluate study design and methodological rigour, risk of bias and confounding, sample size and statistical power, appropriateness of outcome measures, and transparency and completeness of reporting.

Randomised controlled trials typically carry more weight than observational or mechanistic studies, but design alone is not enough. A poorly executed trial may contribute very little to the overall assessment. Importantly, grading frameworks are not used to tick boxes – they inform whether evidence can reasonably support a causal relationship consistent with the proposed claim.

Consistency: why one positive study is rarely enough

Consistency is one of the most influential factors in regulatory decision-making. Regulators consider whether findings are directionally consistent across studies, whether similar outcomes are observed in comparable populations, and whether effects are reproducible under different conditions.

A single positive study alongside neutral or conflicting results weakens confidence, even if that positive study is well designed. Conversely, multiple moderate-quality studies showing consistent effects may be more persuasive than one high-quality outlier.

Relevance: the most common point of failure

Evidence often fails not because it is poor quality, but because it is not sufficiently relevant to the proposed claim. Relevance is assessed across several dimensions.

The study population must align with the intended consumer group. Evidence generated in clinical populations, children, athletes, or older adults may not be transferable to a general adult population without careful justification. Regulators also assess whether the dose used in studies matches the amount actually delivered by the product, and whether the form of the ingredient is comparable in bioavailability and function. Evidence based on doses far exceeding those present in the final product is unlikely to support a claim.

Finally, measured outcomes must correspond directly to the claim wording. Improvements in surrogate markers do not automatically translate into allowable health effects – particularly where therapeutic implications may arise.

Decision logic: conservative by design

Regulatory frameworks are intentionally conservative. Where uncertainty exists, decisions tend to favour consumer protection, prevention of misleading impressions, and clear boundaries between permitted nutrition information and regulated therapeutic claims.

This means evidence must support not only the scientific plausibility of a claim, but also its interpretation by consumers in context. In Australia, these assessments sit within the Food Standards Australia New Zealand Food Standards Code, with marketing and presentation also subject to oversight by the Australian Competition and Consumer Commission.

Why “good enough” is a strategic question, not a scientific one

From a regulatory perspective, “good enough” does not mean interesting, emerging, biologically plausible, or consistent with internal R&D findings. It means the evidence can withstand independent scrutiny, conservative interpretation, and real-world regulatory application.

This is why evidence assessment should occur before claims are drafted or packaging is finalised – not after problems arise.

The bottom line

Regulators are not asking whether evidence is promising. They are asking whether it is sufficient, consistent, and directly applicable to the claim being made. Understanding this decision logic allows food brands to invest in the right evidence, avoid over-reaching claims, and use science strategically rather than defensively.

In a regulatory environment where claims are increasingly scrutinised, clarity on what constitutes “good enough” isn’t optional – it’s foundational.

Food labelling and health claims are complex, and most brands are never taught how to navigate them properly. Labelled & Legit is designed to give food brands clarity, confidence, and a defensible framework for getting labels and claims right before launch. Join the Labelled & Legit waitlist here.